MS Patient Treatment Preferences Diverge From Payers, Physicians
Executive Summary
Survey finds patient assign greatest value to a drug’s effect on multiple sclerosis symptoms.
You may also be interested in...
Tysabri Liability: Biogen's Dialogue With FDA Helps Get Suit Tossed
Judge finds Tysabri label warnings about brain infection were adequate and that there is 'clear evidence' FDA would not have approved a labeling change.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.